Meeting
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
Authors
Ruihua Xu
Sun Yat-Sen University Cancer Center, Guangzhou, China
Ruihua Xu , Yuhong Li , Jiao Ji , Miaozhen Qiu , Yang Zhang , Wenqin Liu , Xiaohong Tian , Su Li , Hengbang Wang , Fenghua Wang , Dongsheng Zhang , Feng Wang , Zhiqiang Wang , Huiyan Luo , Benyan Zou , De shen Wang , Chao Ren , Ying Jin , Yifan Zhai , Dajun Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
20150161
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2593)
DOI
10.1200/JCO.2018.36.15_suppl.2593
Abstract #
2593
Poster Bd #
419
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
First Author: Andrew J. Wagner
Poster
2018 ASCO Annual Meeting
First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).
First Author: Jacob M. Sands
Poster
2018 ASCO Annual Meeting
A phase I molecular adaptive clinical study to evaluate safety and tolerability of BPM31510-IV in advanced solid tumors: Final study results.
First Author: Niven R. Narain
Poster
2016 ASCO Annual Meeting
A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
First Author: Alex A. Adjei